Xi-Wen Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xi-Wen Zhang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Liang Wang
Laboratory of Gynecologic Oncology, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics Fujian Medical University Fuzhou Fujian China
1 shared publication - Liping Zhao
Department of Gynecology and Obstetrics, the Second Hospital of Jilin University, Changchun, 130041, Jilin, China
1 shared publication - Manhua Cui
Department of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China
1 shared publication - Manhua Cui
Department of Gynecology and Obstetrics, the Second Hospital of Jilin University, Changchun, 130041, Jilin, China
1 shared publication - Rulin Yang
Department of Gynecology and Obstetrics, the Second Hospital of Jilin University, Changchun, 130041, Jilin, China
1 shared publication - Tianmin Xu
Department of Gynecology and Obstetrics, The Second Hospital of Jilin University, Changchun, China
1 shared publication
Latest Publications
- Open Access
- 2 March 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (3) , 465
CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy
Ovarian cancer (OC) is among the most common gynecologic malignancies with a poor prognosis and a high mortality rate. Most patients are diagnosed at an advanced stage (stage III or IV), with 5-year survival rates ranging from 25% to 47% worldwide. Surgical resection and first-line chemotherapy are the main treatment modalities for OC. However, patients usually relapse within a few years of initial treatment due to resistance to chemotherapy. Cell-based therapies, particularly adoptive T-cell therapy and chimeric antigen receptor T (CAR-T) cell therapy, represent an alternative immunotherapy approach with great potential for hematologic malignancies. However, the use of CAR-T-cell therapy for the treatment of OC is still associated with several difficulties. In this review, we comprehensively discuss recent innovations in CAR-T-cell engineering to improve clinical efficacy, as well as strategies to overcome the limitations of CAR-T-cell therapy in OC.
- 2 March 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (3) , 465
Open AccessCAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy
Ovarian cancer (OC) is among the most common gynecologic malignancies with a poor prognosis and a high mortality rate. Most patients are diagnosed at an advanced stage (stage III or IV), with 5-year survival rates ranging from 25% to 47% worldwide. Surgical resection and first-line chemotherapy are the main treatment modalities for OC. However, patients usually relapse within a few years of initial treatment due to resistance to chemotherapy. Cell-based therapies, particularly adoptive T-cell therapy and chimeric antigen receptor T (CAR-T) cell therapy, represent an alternative immunotherapy approach with great potential for hematologic malignancies. However, the use of CAR-T-cell therapy for the treatment of OC is still associated with several difficulties. In this review, we comprehensively discuss recent innovations in CAR-T-cell engineering to improve clinical efficacy, as well as strategies to overcome the limitations of CAR-T-cell therapy in OC.
- Open Access
- 1 September 2019
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 117, 109173
Basing on uPAR-binding fragment to design chimeric antigen receptors triggers antitumor efficacy against uPAR expressing ovarian cancer cells
- 1 September 2019
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 117, 109173
Open AccessBasing on uPAR-binding fragment to design chimeric antigen receptors triggers antitumor efficacy against uPAR expressing ovarian cancer cells